These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

534 related items for PubMed ID: 22388296

  • 21. Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial.
    Servoss SJ, Wan Y, Snapinn SM, DiBattiste PM, Zhao XQ, Theroux P, Jang IK, Januzzi JL, PRISM-PLUS trial.
    Am J Cardiol; 2004 Apr 01; 93(7):843-7. PubMed ID: 15050486
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.
    Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo DJ, Sabatè M, Hamon M, Repetto A, Colangelo S, Brugaletta S, Parrinello G, Percoco G, Ferrari R, Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators.
    Circulation; 2009 Jun 30; 119(25):3215-22. PubMed ID: 19528337
    [Abstract] [Full Text] [Related]

  • 24. Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative).
    Alexander D, Mann N, Ou FS, Peterson ED, Ohman EM, Gibler WB, Roe MT.
    Am J Cardiol; 2008 Nov 15; 102(10):1335-40. PubMed ID: 18993151
    [Abstract] [Full Text] [Related]

  • 25. Transfer with GP IIb/IIIa inhibitor tirofiban for primary percutaneous coronary intervention vs. on-site thrombolysis in patients with ST-elevation myocardial infarction (STEMI): a randomized open-label study for patients admitted to community hospitals.
    Dobrzycki S, Kralisz P, Nowak K, Prokopczuk P, Kochman W, Korecki J, Poniatowski B, Zuk J, Sitniewska E, Bachorzewska-Gajewska H, Sienkiewicz J, Musial WJ.
    Eur Heart J; 2007 Oct 15; 28(20):2438-48. PubMed ID: 17884846
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.
    Hermanides RS, van Werkum JW, Ottervanger JP, Breet NJ, Gosselink AT, van Houwelingen KG, Dambrink JH, Hamm C, ten Berg JM, van 't Hof AW, Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group.
    Catheter Cardiovasc Interv; 2012 May 01; 79(6):956-64. PubMed ID: 22162050
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M.
    J Invasive Cardiol; 2000 Dec 01; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
    Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, de Cesare N, Rodriguez AE, Ferrario M, Moreno R, Piva T, Sheiban I, Pasquetto G, Prati F, Nazzaro MS, Parrinello G, Ferrari R, Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators.
    JAMA; 2008 Apr 16; 299(15):1788-99. PubMed ID: 18375998
    [Abstract] [Full Text] [Related]

  • 34. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
    Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schühlen H, Dirschinger J, Berger PB, Schömig A, Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators.
    JAMA; 2006 Apr 05; 295(13):1531-8. PubMed ID: 16533938
    [Abstract] [Full Text] [Related]

  • 35. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial.
    van 't Hof AW, Ernst N, de Boer MJ, de Winter R, Boersma E, Bunt T, Petronio S, Marcel Gosselink AT, Jap W, Hollak F, Hoorntje JC, Suryapranata H, Dambrink JH, Zijlstra F, On-TIME study group.
    Eur Heart J; 2004 May 05; 25(10):837-46. PubMed ID: 15140531
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Beneficial effects of intracoronary tirofiban bolus administration following upstream intravenous treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the ICT-AMI study.
    Zhu TQ, Zhang Q, Qiu JP, Jin HG, Lu L, Shen J, Zhao LP, Zhang RY, Hu J, Yang ZK, Shen WF.
    Int J Cardiol; 2013 May 25; 165(3):437-43. PubMed ID: 21940058
    [Abstract] [Full Text] [Related]

  • 38. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial).
    Bonz AW, Lengenfelder B, Strotmann J, Held S, Turschner O, Harre K, Wacker C, Waller C, Kochsiek N, Meesmann M, Neyses L, Schanzenbächer P, Ertl G, Voelker W.
    J Am Coll Cardiol; 2002 Aug 21; 40(4):662-8. PubMed ID: 12204495
    [Abstract] [Full Text] [Related]

  • 39. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial.
    Bolognese L, Falsini G, Liistro F, Angioli P, Ducci K, Taddei T, Tarducci R, Cosmi F, Baldassarre S, Burali A.
    J Am Coll Cardiol; 2006 Feb 07; 47(3):522-8. PubMed ID: 16458130
    [Abstract] [Full Text] [Related]

  • 40. Left ventricular function after ST-elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial).
    Taglieri N, Saia F, Guiducci V, Tondi S, Conrotto F, Marrozzini C, Rocchi G, Biagini E, Reggiani ML, Giacometti P, Piovaccari G, Manari A, Marzocchi A, FATA Trial Investigators.
    Am J Cardiol; 2009 Mar 15; 103(6):785-90. PubMed ID: 19268732
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.